Introduction
In recent years, large multinational registries have provided novel insights into the characteristics, management and outcomes of the spectrum of patients with acute coronary syndromes (ACS) treated in everyday clinical practice. Several of these studies have reported decreased mortality rates associated with improved adherence to evidencebased ACS treatments [1] [2] [3] . While observational studies offer new and valuable information that cannot be provided in the narrower confines of clinical trials, so far they have been limited largely to European and North American populations. Only limited data are available for ACS patients outside of these regions [4] [5] [6] [7] [8] [9] . Given the anticipated increase in burden of cardiovascular morbidity and mortality predicted for developing countries, it is now imperative to investigate how patients in such countries are being managed and how their outcomes compare with patients in developed countries. These studies have the potential to raise awareness of the disease and identify opportunities for improved treatment and patient outcomes.
The aim of the multinational observational ACute Coronary Events -a multinational Survey of current management Strategies (ACCESS) registry was to describe the characteristics, management and 1-year outcomes of patients hospitalized with non-ST-segment elevation ACS (NSTE-ACS) or ST-segment elevation myocardial infarction (STEMI) in countries in Africa, Latin America, and the Middle East [10] . In this report, we describe the data for patients enrolled in three countries in western North Africa (''Maghreb'').
Methods
The rationale and methods for the ACCESS study have been described in detail elsewhere [10] . ACCESS is a prospective, multinational, observational registry of patients hospitalized for an ACS. Patients were enrolled between January 2007 and January 2008 at 134 sites in 19 countries in western North Africa (''Maghreb'': Algeria, Morocco, Tunisia), South Africa, Latin America (Argentina, Brazil, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Venezuela) and the Middle East (Egypt, Iran, Jordan, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates).
The registry was conducted in accordance with the guidelines for Good Epidemiological Practice and under the leadership of a scientific advisory board. Participating countries were responsible for ensuring that the study was performed in accordance with local regulations. Local institutional review boards or independent ethics committees approved the study and all patients provided signed informed consent.
Study setting and site selection
A questionnaire was sent to all potential sites to collect data on the type of institution (public, private, teaching), its location, the number of ACS patients treated and the services offered. The affiliate in each country then provided a list of centres that represented their country as completely as possible. The final list of investigators (including cardiologists and internists) was then randomly generated by the trial manager. Physicians who declined to participate were replaced by the following physician in the list. The aim was to enroll approximately 25 patients per site, with at least 20 sites per country.
Study population
Eligible patients were those aged 21 years or above admitted to hospital for an ACS. Patients with symptoms precipitated by a comorbidity such as anaemia, heart failure or noncardiac trauma, and patients participating in concomitant clinical trials, were excluded. Patients were recruited consecutively to avoid selection bias.
Patients had to present ischaemic symptoms of ACS within 24 hours of hospital presentation and have one or more of the following characteristics: • an increase in a cardiac biochemical marker of myocardial necrosis (troponin or CK-MB).
Evaluations and clinical outcomes
A standardized case report form (see Appendix B in Montalescot et al. [10] ) was used to record data prospectively at hospital admission, at discharge, and at 6 ± 1 and 12 ± 1 month follow-up. Data were collected during follow-up visits or by telephone calls to the patient or a third party (e.g. relative/friend, family physician). The data collected at baseline, included demographics, medical history, risk factors, physical examination, cardiac biomarkers, anklebrachial index, Killip class, chronic medical treatments and health insurance status. Data collected at discharge from hospital included discharge status and diagnosis, hospital management, cardiac biomarkers and hospital events. Follow-up data included clinical outcomes after discharge including those leading to rehospitalization, and treatments since discharge or previous follow-up. Data quality control was performed by trained personnel at ≥ 10% of sites chosen at random in each country. All case report forms were monitored for source documentation and accuracy. Data-request forms were generated automatically in response to queries and resolved by the site investigators.
The primary endpoint was all-cause death at 1 year. Secondary endpoints (at 1 year) were cardiovascular death; non-fatal stroke; non-fatal MI; bleeding; and the combined endpoint of cardiovascular death, stroke or MI [11] . Allcause death at 30 days was also recorded. Full definitions for selected evaluations and outcomes are given in the Appendix.
Statistical analysis
The study population comprised patients enrolled in the French-speaking Maghreb countries (Algeria, Morocco and Tunisia) participating in ACCESS.
Statistical analyses were performed at the 5% significance level, using two-sided tests or two-sided confidence intervals (CIs). Continuous data are given as mean ± standard deviation (SD) or median (interquartile range). A P value ≤ 0.05 was considered to be statistically significant. Categorical data are summarized using counts and percentages. Data were analysed with the SAS package, release 9.1.3 (SAS Institute, Cary, NC).
Funding
The ACCESS registry was sponsored by Sanofi-Aventis, Paris, France.
Results
A total of 1720 patients were recruited by 144 physicians at 21 sites in Algeria, 28 sites in Morocco and 15 sites in Tunisia between January 2007 and January 2008. Most of the participating physicians were non-interventional (57.6%) or interventional (34.7%) cardiologists, while 4.9% were hospital physicians and 2.8% were internists.
Study population
The patient flow chart is shown in Fig. 1 . Of the 1720 patients enrolled, 33 with ''other cardiac'', ''other'' or missing diagnoses were excluded. A total of 1687 patients had a confirmed ACS diagnosis: 59% with STEMI and 41% with non-ST-elevation ACS (NSTE-ACS). Over the course of the study, 139 patients died, 95 were lost to follow-up, two withdrew consent, and 22 were excluded for another reason. Data were available for 1687 patients, 1429 of who had 1-year follow-up data (85% of the Maghreb population).
The baseline characteristics of the population are given in Table 1 . The overall population comprised 79% Caucasians and 20% Arabs. Patients with NSTE-ACS were slightly older than those with STEMI and had a more frequent medical history of angina, myocardial infarction, and congestive heart failure. Patients with STEMI were more commonly men, and were more likely to be tobacco smokers and to misuse alcohol. The mean (SD) GRACE risk score [12] was 119.6 (36.9).
The median (Q1, Q3) delay from onset of symptoms to hospital admission was 7.0 (3.0, 23.7) hours, and was shorter among STEMI patients than NSTE-ACS patients (6.0 [2.8, 18.2] vs 10.4 [3.0, 33.6] hours).
Almost one-third (n = 511, 31%) of patients had no medical insurance; the remaining patients had government insurance (n = 1042, 62%), private insurance (n = 107, 6.4%) or both (n = 12, 0.7%).
Management in hospital and at discharge
Information on in-hospital management according to discharge diagnosis is given in Table 2 . Most ACS patients (n = 1625, 96%) received aspirin, a statin (n = 1510, 90%) and an angiotensin-converting enzyme inhibitor (n = 1249, 74%) or angiotensin II receptor antagonist (n = 111, 6.6%). A thienopyridine was used in 77% (n = 1293) of patients, beta-blockers in 83% (n = 1401) and intravenous glycoprotein IIb/IIIa inhibitor in 9.7% (n = 164). Of the 989 patients with STEMI, 30% (n = 298) received fibrinolytic therapy, most frequently with streptokinase (92%), followed by tenecteplase (6.4%) and alteplase (1.7%).
During the initial hospitalization, coronary angiography was done in less than half of the patients (n = 757, 45%). Percutaneous coronary intervention (PCI) was performed in 22% of patients with NSTE-ACS and in 27% with STEMI, 97% of whom received a stent ( Table 2) . Forty-two per cent (n = 419) of eligible STEMI patients received no form of acute reperfusion therapy (i.e. PCI or fibrinolytic therapy within 24 hours of admission to hospital).
Selected treatments at discharge from hospital are shown in Table 3 . A large proportion of patients were treated with aspirin (94%), statins (84%), beta-blockers (82%) and thienopyridines (73%).
Country comparisons
Both in-hospital and at discharge, the highest rates of use of angiotensin-converting enzyme/angiotensin II Data are %. ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; CABG: coronary artery bypass graft; NSTE-ACS: non-ST-segment elevation acute coronary syndrome; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction. 
Clinical outcomes
The rate of 30-day all-cause death was 4.1% rising to 8.1% by 12 months, and did not differ between ACS subgroups ( Table 5 ; P = not significant). Kaplan-Meier survival curves show an early risk of death up to approximately 50 days, which was similar in both ACS subgroups ( Fig. 2 ; P = not significant). The 12-month event rates for the other outcomes are shown in Table 5 . The rate of cardiovascular death was 6.2% overall, and was slightly but not statistically significantly lower among patients with NSTE-ACS versus STEMI. Non-fatal stroke occurred in 2.3% of ACS patients, non-fatal myocardial infarction in 4.4% and bleeding in 4.1%. The composite of non-fatal outcomes plus cardiovascular death was 12%, and was consistent across ACS subgroups.
Among the 136 patients who died within 12 months of presentation for an ACS, the most common reasons were ''other'' cardiovascular death (including sudden death of unknown cause; 38%) and myocardial infarction (32%). Deaths were due to strokes in 5.9% of patients and for noncardiovascular reasons in 5.1%. The remaining deaths (18%) were of unknown cause.
When analysed by country, the rates of all-cause death (both overall and in the NSTE-ACS subgroup) were lowest in Tunisia, intermediate in Morocco and highest in Algeria (Fig. 3) .
According to a Cox proportional hazards model, factors associated with a higher risk of death at 12 months were cardiac arrest during initial hospitalization (hazard ratio [HR] 13.41, P < 0.0001), cardiogenic shock during hospitalization (HR 4.66, P < 0.0001), bleeding during hospitalization (HR 2.78, P = 0.0055), age (HR 1.67, P = 0.0083) and history of diabetes (HR 1.44, P = 0.055). Factors associated with a lower risk were male sex (HR 0.63, P = 0.014) and PCI (HR 0.25, P < 0.001).
Discussion
The present study reports on the contemporary management and outcomes for 1687 patients hospitalized for an ACS in three countries in western North Africa -Algeria, Morocco and Tunisia. Fifty-nine per cent of the patients were given a discharge diagnosis of STEMI and the remaining 41% a diagnosis of NSTE-ACS. Patients with STEMI were slightly younger than those with NSTE-ACS, were more likely to be male, have a less frequent history of cardiac disease, fewer risk factors and a lower systolic arterial blood pressure; they did, however, have a higher heart rate and were more often tobacco smokers and heavy drinkers. The all-cause mortality rate rose from 4.1% at 30 days to 8.1% at 1 year and did not differ between ACS subgroups.
Maghreb population vs other observational data
The patients enrolled in the Maghreb countries differed from those in the overall ACCESS population, which involved 11,731 patients with an ACS [10] , and in which 54% were diagnosed with NSTE-ACS versus only 41% in Maghreb. The proportion of NSTE-ACS patients in the Maghreb population is much lower than that reported in predominantly ''Western'' ACS populations such as the Global Registry of Acute Coronary Events (GRACE) (66%) [13] and the second Euro Heart Survey (EHS-ACS-II) (48%) [3] , but also in Arab populations as shown in the Gulf RACE study (61%) [13] . In the Indian CREATE registry, however, which involved over 20,000 ACS patients (mean age 58 ± 12 years), 39% were diagnosed with NSTE-ACS.
The Maghreb ACCESS ACS population appears intermediate between the GRACE registry and the Gulf RACE registry in terms of mean age at presentation (60 years vs 66 years in GRACE and 56 years in Gulf RACE), proportion of men (76% vs 69% and 76%) and rate of hypertension (45% vs 66% and 50%). In the STEMI population, however, the proportion of patients with diabetes mellitus was highest in the Maghreb patients (34% vs 22% in GRACE and 32% in Gulf RACE).
When compared with the overall ACCESS data [10] , patients in Maghreb had lower rates of cardiac risk factors, medical histories of angina, cardiac disease and bleeding, and family histories of cardiovascular disease. In contrast, a greater percentage of Maghreb patients were tobacco smokers. The rate of smoking was also higher than reported in other observational studies (40% vs 28% in GRACE and 37% in Gulf RACE [13] ), was the same as in the CREATE registry (40%) [7] , but was lower than in a Tunisian study of patients with myocardial infarction (63%) [8] .
These differences suggest that patients in the Maghreb region, similar to those in the Indian CREATE registry, tend to present at a younger age. They also suggest insufficient public awareness of the negative impact of smoking on cardiovascular disease, and provide an incentive to encourage the adoption of anti-smoking campaigns and smoking bans in public areas.
Variations in management
When compared with the overall ACCESS population [10] , the use of beta-blockers (83% vs 78% overall) and aspirin (96% vs 93% overall) was slightly higher in the Maghreb countries, and was in line with the results reported for other studies (≥ 95%) [1, 3] . Similarly, Maghreb physicians showed a preference to use the low-molecular-weight heparin enoxaparin (76% in Maghreb vs 57% in overall ACCESS) over unfractionated heparin (24% vs 37%) in patients with NSTE-ACS. In line with the overall data, other, newer anticoagulants such as fondaparinux or bivalirudin were almost never used. Coronary angiography (45% in Maghreb vs 58% overall ACCESS) and PCI (25% vs 35% overall) were performed much less frequently in Maghreb when compared with the overall ACCESS population [10] and other registry studies such as GRACE and EHS-ACS-II [1, 3] , but were used substantially more frequently than in the Gulf RACE study (21% for coronary angiography and 7% for PCI) [6] or the Indian CREATE registry (23% and 7.5%, respectively) [7] . Among patients with STEMI or left bundle branch block, the Gulf RACE data showed a very high rate of use of thrombolysis (93%; 65% overall rate of reperfusion), compared with only 30% (58% overall rate of reperfusion) in STEMI patients in Maghreb. Similarly, the CREATE registry reported a higher rate of reperfusion with fibrinolytic therapy for patients with STEMI (59%) but a very low rate of in-hospital PCI (8.0%) [7] .
At discharge from hospital, the use of evidencebased ACS medications including aspirin, ACE inhibitors/ angiotensin-converting enzyme receptor blockers, beta-blockers and statins was reassuringly high, and was greater than in the overall ACCESS registry [10] .
Clinical outcomes
The rate of all-cause 30-day mortality in the Maghreb ACCESS population was higher than that in the overall ACCESS population (4.1% vs 3.6%) [10] , driven by a higher rate of death among patients with NSTE-ACS (4.0% vs 2.4%) and despite the lower rate among STEMI patients (4.2% vs 5.0%). This difference was maintained at 12 months for both all-cause and cardiovascular deaths. While the Maghreb population shares some similarities with the Indian CREATE registry [7] , the rate of death at 30 days in STEMI patients was 50% lower (4.2% vs 8.6%), perhaps reflecting the very low rate of the primary PCI in the Indian population. In comparison, the rate of 30-day death among patients with NSTE-ACS was marginally higher in ACCESS (4.0% vs 3.7%). These differences in outcome may be due to variations in clinical management, but also to socioeconomic divisions such as disparity in treatments, type of hospital, and delays to presentation and treatment [7] . The low rates of 30-day death in ACCESS may also reflect the GRACE risk score (mean of 119.6 [36.9]), which corresponds to an intermediate risk of death in patients with NSTE-ACS and a low risk among those with STEMI [12] .
The 12-month rates of non-fatal stroke, non-fatal myocardial infarction and the composite of cardiovascular death, non-fatal stroke and non-fatal myocardial infarction were also slightly higher in the Maghreb subgroup compared with the overall ACCESS population [10] , whereas the rates of bleeding were lower, perhaps reflecting differences in the use of pharmacological therapies with potential bleeding complications.
The rate of death in the STEMI population was highest in Morocco and lowest in Tunisia. These findings are unexpected, taking into account the greater use of reperfusion in Morocco, and suggest the presence of unmeasured factors such as, for example, differences in extent of disease and delayed thrombolysis or PCI.
Limitations
This observational study is subject to limitations and biases, including the collection of non-randomized data, incomplete information (including loss to follow-up), potential confounding by drug indication, dosage, or other unmeasured covariates, and potential bias in site selection. The patients may not be wholly representative of their countries and may not reflect trends in other countries in Africa.
Conclusions
These observational data, from three countries in western North Africa, provide insights into the clinical characteristics, risk factors, management and outcomes for patients hospitalized for an ACS. These findings demonstrate the need for strategies aimed at cardiovascular disease prevention, as evidenced by the high rates of diabetes mellitus, smoking and alcohol misuse. Greater adherence to evidence-based strategies of cardiovascular disease treatment, including more extensive use of reperfusion therapy, especially primary PCI, alongside reduction in risk factors, may in time lead to reductions in the rates of death due to cardiovascular diseases.
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Appendix. Study definitions used in ACCESS

Event Definition
Cardiovascular death Any death with a clear cardiac or vascular cause (including hemorrhagic death of any origin and fatal pulmonary embolism) or unknown cause (including sudden death, unobserved and unexpected death, and other death not definitely attributed to a non-vascular cause)
Myocardial infarction [14] Patients who did not undergo a cardiac intervention within the previous 24 hours. At least one of the following must be present: Bleeding (GUSTO [11] ) Grade I: severe bleeding: documented intracranial hemorrhage or bleeding that causes hemodynamic compromise requiring blood or fluid replacement, inotropic support, ventricular assist devices, surgical intervention (other than vascular site repair), or CPR to maintain a sufficient cardiac output Grade II: moderate bleeding: bleeding that requires transfusion of blood but does not lead to hemodynamic compromise requiring intervention Grade III: mild bleeding: bleeding not requiring transfusion and not causing hemodynamic compromise, including subcutaneous bleeding, mild hematomas, oozing from puncture sites, etc.
